Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 5/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21020024 | 0.91 | DDR1 (0.33) | KCNH2DDR1CNR2NPC1RAB9A | |
| SCHEMBL17949520 | 0.90 | DDR1 (0.35) | DDR1 | |
| SCHEMBL21020025 | 0.87 | S1PR1 (0.34) | DDR1 | |
| SCHEMBL17949386 | 0.87 | PDE10A (0.35) | KCNH2DDR1CNR2 | |
| SCHEMBL21019898 | 0.87 | DDR1 (0.32) | KCNH2DDR1CNR2NPC1RAB9A | |
| SCHEMBL17949562 | 0.85 | SMN1; SMN2 (0.32) | KCNH2DDR1CNR2NPC1RAB9A | |
| SCHEMBL31534718 | 0.84 | KCNH2 (0.38) | KCNH2DDR1CNR2NPC1RAB9A | |
| SCHEMBL17967732 | 0.84 | KCNH2 (0.38) | KCNH2DDR1CNR2NPC1RAB9A | |
| SCHEMBL18015922 | 0.84 | PDE10A (0.35) | KCNH2DDR1CNR2 | |
| SCHEMBL20465862 | 0.83 | PTGER4 (0.34) | KCNH2DDR1CNR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190150447-A1 | CONDENSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190150447-A1 | CONDENSED HETEROCYCLIC COMPOUND | CBR3, CBR1, RCOR3 | KCNH2 830/4885DDR1 3656/4885CNR2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.